fda warning letters compounded semaglutide november 2025 Drug compounders sue over declaration ending Wegovy shortage FDA Sends Warning Letters to

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial

While the study found that semaglutide specifically reduced the risk of atrial arrhythmias and atrial fibrillation (AF), other studies have reported conflicting results regarding the arrhythmia risk associated with GLP-1 RAs ( GLP-1RAs have been shown to significantly reduce postprandial levels of triglycerides, apolipoprotein (Apo) B48 and ApoC-III, independently of gastric emptying

Enter Amble

Methylmalonic Acid (MMA) Test: Doesnt check B12 directly, but if MMA is high, it usually means your body isnt absorbing/using B12 properly, even if your B12 levels look normal

The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs

Not every patient qualifies, and prescriptions are issued only when clinically appropriate